Welcome to our dedicated page for EyePoint news (Ticker: EYPT), a resource for investors and traders seeking the latest updates and insights on EyePoint stock.
The EyePoint, Inc. (EYPT) news page on Stock Titan aggregates company-reported updates and market-moving announcements for this clinical-stage biopharmaceutical business focused on serious retinal diseases. EyePoint’s disclosures emphasize its lead investigational product, DURAVYU™ (vorolanib intravitreal insert), and its progress through late-stage clinical development, making corporate news particularly relevant for investors tracking ophthalmology and retinal therapeutics.
Visitors can review news covering clinical milestones, such as enrollment completion and data safety monitoring committee recommendations for the Phase 3 LUGANO and LUCIA trials in wet age-related macular degeneration (wet AMD), as well as the design and initiation of the pivotal Phase 3 COMO and CAPRI trials in diabetic macular edema (DME). Company releases also highlight Phase 2 data from the DAVIO 2 and VERONA studies, which EyePoint cites as demonstrating meaningful and sustained improvements in vision and anatomy with favorable safety profiles.
In addition to clinical trial updates, EyePoint’s news includes financing and corporate developments, such as underwritten public offerings, at-the-market equity programs, and inducement grants under Nasdaq Listing Rule 5635(c)(4). These items provide context on how the company funds its DURAVYU programs and earlier-stage pipeline initiatives. Investors can also follow announcements about conference presentations at major healthcare and ophthalmology meetings and investor conferences, where EyePoint discusses its clinical data, trial designs, and development strategy.
By monitoring the EYPT news feed, readers can see how EyePoint communicates progress on its investigational sustained-delivery approach, interactions with regulators, and key risk disclosures referenced in forward-looking statements. This page is useful for those who want a centralized view of EyePoint’s official announcements, ranging from clinical milestones and safety updates to capital-raising activities and corporate governance events.
EyePoint Pharmaceuticals (NASDAQ: EYPT) has announced the granting of non-statutory stock options to four new employees as inducement awards outside the Company's 2023 Long-Term Incentive Plan. These grants, approved by the Compensation Committee, are in accordance with NASDAQ Listing Rule 5635(c)(4). The stock options, totaling 69,000 shares of EyePoint Pharmaceuticals common stock, were granted on October 15, 2024, with an exercise price of $9.88 per share.
The options have a ten-year term and vest over four years, with 25% vesting on the first anniversary and the remainder vesting in equal monthly installments over the following three years. Vesting is subject to continued service with the company.
EyePoint Pharmaceuticals (NASDAQ: EYPT) has granted non-statutory stock options to two new employees as inducement awards outside its 2023 Long-Term Incentive Plan. The grants, approved by the Compensation Committee, comply with NASDAQ Listing Rule 5635(c)(4). Key details include:
- 43,000 shares of common stock options granted
- Grant date: September 13, 2024
- Exercise price: $9.10 per share (closing price on grant date)
- Ten-year term
- Vesting over four years: 25% after one year, remainder in monthly installments over three years
- Vesting contingent on continued employment
These inducement awards aim to attract and retain talent in EyePoint's mission to develop therapeutics for serious retinal diseases.
EyePoint Pharmaceuticals (NASDAQ: EYPT) has appointed Fred Hassan, a distinguished industry leader, to its Board of Directors. This strategic move comes as the company prepares for the Phase 3 LUGANO trial of DURAVYU™ in wet age-related macular degeneration (AMD) and future commercialization. Hassan, former CEO of three global pharmaceutical companies, brings extensive biopharmaceutical experience to EyePoint.
Simultaneously, Anthony P. Adamis, M.D. and David Guyer, M.D. have resigned from the Board due to their transition to full-time roles at Merck & Co. The company acknowledges their contributions in shaping EyePoint's product development pipeline and clinical strategies.
EyePoint Pharmaceuticals (NASDAQ: EYPT), a company focused on developing innovative therapeutics for serious retinal diseases, has announced its participation in several upcoming investor conferences. These include:
- Morgan Stanley Annual Global Healthcare Conference (September 4, 2024)
- Baird Global Healthcare Conference (September 10, 2024)
- Cantor Global Healthcare Conference (September 18, 2024)
- UBS Virtual Ophthalmology Day (October 2, 2024)
The company will engage in various formats, including 1x1 investor meetings and fireside chats. Live webcasts and archived replays of the presentations will be available on the company's website.
EyePoint Pharmaceuticals (NASDAQ: EYPT) has granted non-statutory stock options to nine new employees as inducement awards outside its 2023 Long-Term Incentive Plan. The company, focused on developing therapeutics for serious retinal diseases, issued options to purchase up to 106,600 shares of common stock on August 15, 2024. These grants, approved by the Compensation Committee, have an exercise price of $8.20 per share, matching the closing price on the grant date. The options have a ten-year term and vest over four years, with 25% vesting on the first anniversary and the remainder in equal monthly installments over the following three years, subject to continued employment.
EyePoint Pharmaceuticals (NASDAQ: EYPT), a company focused on developing innovative therapeutics for serious retinal diseases, has announced its participation in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference. The event will take place on Thursday, August 15th, 2024.
Dr. Jay S. Duker, President and CEO of EyePoint, will present a Company Overview available on-demand from 7:00 a.m. ET. Additionally, he will participate in a panel discussion on 'The Evolving Therapeutic Landscape of AMD' at 9:00 a.m. ET.
Investors can access live webcasts and archived replays of both presentations through the Investors section of EyePoint's website. The replay will remain available for 90 days after the event.
EyePoint Pharmaceuticals (NASDAQ: EYPT) reported Q2 2024 financial results and corporate updates. Key highlights include:
1. Phase 3 LUGANO trial of DURAVYU™ for wet AMD on track for first patient dosing in 2024.
2. Positive 12-month data from Phase 2 DAVIO 2 trial of DURAVYU in wet AMD.
3. Phase 2 VERONA trial of DURAVYU in DME fully enrolled; topline data expected Q1 2025.
4. $280.2 million cash and investments as of June 30, 2024.
5. Q2 2024 total net revenue: $9.5 million.
6. Net loss: $30.8 million, or ($0.58) per share.
7. Cash runway through Phase 3 wet AMD topline data for DURAVYU in 2026.
EyePoint Pharmaceuticals (NASDAQ: EYPT) has granted non-statutory stock options to nine new employees as inducement awards outside its 2023 Long-Term Incentive Plan. The company, focused on developing therapeutics for serious retinal diseases, issued options to purchase up to 57,700 shares of common stock on July 15, 2024. These grants, approved by the Compensation Committee, have an exercise price of $10.54 per share, matching the closing price on the grant date. The options have a ten-year term and vest over four years, with 25% vesting on the first anniversary and the remainder in equal monthly installments over the following three years, subject to continued employment.
EyePoint Pharmaceuticals will highlight the clinical and regulatory progress of DURAVYU™ (vorolanib intravitreal insert) and pipeline innovations at their R&D Day on June 26, 2024. Key updates include the Phase 3 trial design for LUGANO and LUCIA pivotal trials in wet AMD scheduled for 2H 2024 following a positive FDA meeting, and positive twelve-month safety and efficacy data from the Phase 2 DAVIO 2 trial. DURAVYU shows promise as a six-month maintenance therapy with no serious adverse events reported. The VERONA Phase 2 trial in diabetic macular edema has completed enrollment. EyePoint aims to advance DURAVYU as a significant treatment for VEGF-mediated retinal diseases.
EyePoint Pharmaceuticals (NASDAQ: EYPT) announced it will host an R&D Day on June 26, 2024, from 8:00 a.m. to 9:30 a.m. ET.
The event will feature esteemed KOL speakers Dr. Carl D. Regillo and Dr. Yasha S. Modi, who will discuss the science behind DURAVYU™ (vorolanib intravitreal insert).
The agenda includes an overview of DURAVYU™, positive Phase 2 DAVIO 2 trial results in wet AMD, and Phase 3 trial plans.
A roundtable discussion will be moderated by EyePoint's President and CEO, Jay S. Duker, M.D.
Access to the live event and replay is available on the EyePoint website.